The recent advances in prostate cancer research have resulted in the development of a plethora of novel therapeutics for the treatment of metastatic castration-resistant prostate (mCRPC) that have been either already approved by Health Canada / FDA or are in late Phase III clinical trials. In what was once a barren treatment landscape, physicians will soon have the ability to choose from a menu of various pharmaceuticals with a wide range of mechanisms of actions: from inhibition of the RANK ligand to CYP17 inhibitors.

**RECENT APPROVALS**

Recently, 2 novel agents have been approved by Health Canada and the US Food and Drug Administration (FDA) for the treatment of advanced prostate cancer: denosumab (Xgeva™, Amgen Canada) for patients with advanced prostate cancer to prevent skeletal related events, and, cabazitaxel (Jenuvax™, sanofi-aventis Canada) for patients with mCRPC who have progressed while on docetaxel. Other new drugs, including Sipuleucil T (Provenge®, Dendreon Corporation) and abiraterone (Zytiga™, Centocor Ortho Biotech, Inc) have recently been approved in the US. Other therapies expected to be approved in North America within the next 2-3 years include MDV-100 (Medivation, Inc.), OGX-011 (Custirisin, OncoGenex Pharmaceuticals, Inc), and TAK-700 (Takeda Pharmaceutical Company Limited).

**Disclosure:**

The author declares no potential conflicts of interest pertaining to this report.

**References**


**Advanced prostate cancer treatment**

**Drug selection and sequencing**

*Alan So, MD, FRCSC*

The authors declare no potential conflicts of interest pertaining to this report.

**Disclosure:**

The authors declare no potential conflicts of interest pertaining to this report.